{"name":"DBV Technologies","slug":"dbv-technologies","ticker":"","exchange":"","domain":"","description":"DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing \"Viaskin\" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":5636000,"revenueGrowth":35.8,"grossMargin":0,"rdSpend":116682000,"netIncome":-146947000,"cash":233718000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Viaskin Milk 300 mcg","genericName":"Viaskin Milk 300 mcg","slug":"viaskin-milk-300-mcg","indication":"Other","status":"phase_1"},{"name":"Viaskin PT 25 mcg","genericName":"Viaskin PT 25 mcg","slug":"viaskin-pt-25-mcg","indication":"Other","status":"phase_1"},{"name":"Viaskin Peanut 250µg","genericName":"Viaskin Peanut 250µg","slug":"viaskin-peanut-250-g","indication":"Treatment of peanut allergy","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"DBV712","genericName":"DBV712","slug":"dbv712","indication":"Peanut allergy (oral immunotherapy tolerance induction)","status":"phase_3"}]}],"pipeline":[{"name":"DBV712","genericName":"DBV712","slug":"dbv712","phase":"phase_3","mechanism":"DBV712 is an epicutaneous immunotherapy (EPIT) that delivers allergen to the immune system through the skin to induce immune tolerance.","indications":["Peanut allergy (oral immunotherapy tolerance induction)"],"catalyst":""},{"name":"Viaskin Milk 300 mcg","genericName":"Viaskin Milk 300 mcg","slug":"viaskin-milk-300-mcg","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Viaskin PT 25 mcg","genericName":"Viaskin PT 25 mcg","slug":"viaskin-pt-25-mcg","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Viaskin Peanut 250µg","genericName":"Viaskin Peanut 250µg","slug":"viaskin-peanut-250-g","phase":"phase_3","mechanism":"Viaskin Peanut 250µg is an epicutaneous immunotherapy that works by gradually increasing tolerance to peanut allergens.","indications":["Treatment of peanut allergy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxOcnk3Wi1FekluYjI3SVYwOHBsaVBhM0VmdkQ2UGIzVTRCTVU5RGgzeXphWlhyc2x6T3RQcXdUU21LMERpaU01cl9zSHdveVpDdlFIbzFra1JBSjlHQ2JDZmJQdGtReTF1QzZfQU9QQ3g2c2I2d1BvbjBVSmw2aHQ4c09GSEFhQ0JlbkxxTjZTMDdlbURRWmhwTW1JVjFLaTlUTDNYaUxGT3hGZm5YQlFjeklJcmFZcXduUlM1VE5BNWp0VFdlTloxbDhPMGd3Um5fbkxZdms5NA?oc=5","date":"2026-04-08","type":"pipeline","source":"Idéal Investisseur","summary":"DBV Technologies Stock Up +187% Over the Year and Testing a Key Technical Threshold - Idéal Investisseur","headline":"DBV Technologies Stock Up +187% Over the Year and Testing a Key Technical Threshold - Idéal Investisseur","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQUndnZjdDU1VOdFBjVGo5emlZWHJxN3ZnYS15WDloUnVNeldyMGNMZnM1dGoxa0pfV2VkdkRDdTdqSGpKNzVrVkhvSzVxUEtlVWhLZ1FiSmtQSkQ5TkQwOWVGdkwydWw3ajBaRkdCS0l3V3EwVVRDNzA4UC0xTnJiOUNhUjNyemtYajVGUkFxS3BSRVF4eHl6YmFHa0d1TWx0UEllcHVXMXVEVG13YlNKTVdjR0NqTlZzc25iZmZoaXNxQk0?oc=5","date":"2026-04-02","type":"pipeline","source":"Idéal Investisseur","summary":"DBV Technologies Shares Drop 4.67% Despite a 210% Surge Over the Year - Idéal Investisseur","headline":"DBV Technologies Shares Drop 4.67% Despite a 210% Surge Over the Year - Idéal Investisseur","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxQSS1USkdmSC1mOEJRa2RGMHlsVUUxNkdsdHJENkh3SERzSlVzVWl4VVhWUEZQdllGWDJ3SW1QRXlvT2V1VmoxR3lhNUsxNjBjS3oyczJ1cHZCc2JhOTdrX0FRY1dNeTYyOGRhQXlwaU5fQ0dLYTFsZGQ1bFozTEY3T0Q3Q2p4SUt4M3VMd2xrX0haT054U2czSHlRVnhJZDBwRFQ2Q2ZXUjdESlgxSkxhdVlnUUY1a3Q4LS1ZUk4zR0dVT2tGZzVLeGdwcnBSOXFjd2lHQmphV2F1SlZiazBWbzJjM3ZqTlMwZ0N6aXBnOTJnZDA?oc=5","date":"2026-03-27","type":"pipeline","source":"Idéal Investisseur","summary":"DBV Technologies Bolsters Cash Reserves but Accelerates Cash Burn Ahead of U.S. Launch of Viaskin Peanut - Idéal Investisseur","headline":"DBV Technologies Bolsters Cash Reserves but Accelerates Cash Burn Ahead of U.S. Launch of Viaskin Peanut - Idéal Investi","sentiment":"neutral"},{"date":"2026-03-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOMzJya3FqVjhLd2J0bmhSWV9hMTRDcmRGdy1nS3ExYkZZZnM2VFVsSy1SOHZldkJmMVhKaUhJZTdWaWZpYlJ3UW1EazFNZFB5RG5EcEIxUFZfWnpaQmNiaVZnSEE1aTZtRW9sUllDdHBiREJVbUc4eGlZWXVnVWF3eC1WZ3hQZ2ZzeFFr?oc=5","date":"2025-12-17","type":"regulatory","source":"BioPharma Dive","summary":"Peanut allergy patch succeeds in late-stage study 5 years after FDA rejection - BioPharma Dive","headline":"Peanut allergy patch succeeds in late-stage study 5 years after FDA rejection","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPVEJJSm52TF9UZGVEV3JtUkEtS1ZiTXBQS2dZWjhlZ1lfUlZxTnRqZXZWU281YkJ1SXVtRTIyaEpNbUVpOHIwNW5nX09UYzBYdU1vQ2o2ZDhCUnBIUGJNRUNRQzZXOU1yU1JkX1pPaUowbk9BamREajZxN0RqQXA1bUI5QVk2WGk3TEE?oc=5","date":"2025-12-17","type":"pipeline","source":"pharmaphorum","summary":"DBV gets peanut allergy therapy programme back on track - pharmaphorum","headline":"DBV gets peanut allergy therapy programme back on track","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTFByYmlWVzNfdjU5QXhVQUh4YWc4ZGxJcWdXOFdGZkZGU2FyY0JqVG1RcUVvck9VY1BhcEdCaDd3azk5YlBzSjB3V0laY0N3bUdlRHFZdGl5RnFJQy03aEgzZHNSUzdkVTNrVWloZnVpYw?oc=5","date":"2025-12-17","type":"trial","source":"medwatch.com","summary":"DBV Technologies receive positive results in key study with peanut patch - medwatch.com","headline":"DBV Technologies receive positive results in key study with peanut patch","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPMVVnWWNtTjQ0ajVTRm1wNjNFRElIUzJxdXR0QVRsaUV4SzR1dF9fbWV0T2JXRENXaHhWRk10RS1jNTluQVVrTGxjYVNvRXFIX3lvdnR2UzVmRkRSRmJXVWtCZGhkUjZpWDNJTTA5dmYxdjVGOVZET3dlcTBSNVMyUi1vdE1xSUQyaDJMVkFSeEZPRFJM?oc=5","date":"2025-12-17","type":"trial","source":"The Pharma Letter","summary":"DBV shares up by a third on persuasive peanut allergy data - The Pharma Letter","headline":"DBV shares up by a third on persuasive peanut allergy data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNbm1Sc0hBWU50VS1ldWdfWDY1VEs5SVdDSUpNSEI5RHh6bV9BNGp5aEc1dWlBTThzVWM3WFVlZ0pmaVlqNEFlM25iM1VxODV3TFJJTzBhYm9TanNVbEF1OHpoYmtvczRHRDQzcFFqT1RJTGJsS19OeHppVlhacEtRREcyZ1QzVDVUV1BDMjM1bmt4ZUx1NXF1WA?oc=5","date":"2025-12-17","type":"pipeline","source":"Investor's Business Daily","summary":"Did This Biotech Just Solve Peanut Allergies? Shares Catapult. - Investor's Business Daily","headline":"Did This Biotech Just Solve Peanut Allergies? Shares Catapult. - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBnMkt1eFB3dXdNMzNTaTdtZlVCbGY1M2F2b0VpYWtZWXlhVjRaeDJrVmZfQVNBWUhOYjB0eXlzdFVNNkd2N3FIMi1HNWZVWjZaYnow?oc=5","date":"2025-12-16","type":"pipeline","source":"FirstWord Pharma","summary":"DBV's peanut allergy patch finally finds clinical success, sending shares soaring - FirstWord Pharma","headline":"DBV's peanut allergy patch finally finds clinical success, sending shares soaring","sentiment":"neutral"},{"date":"2025-12-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNYXd1Y25feUo5R3dMLWJycXZZdTJJZkNUMDd3NENwbG82UnhaTHR0UUowV0RXMEcyM2JtY2NiUGJqU2RKOXE1bE5zU08ySk1KX01KOXQ4Y2x0LTZzQm1QUU56anhYbU9pYnlqRFY2TDNQY1hIVWcyZEI1OEl3Y3RXWm85WThxdU9OWnRsR1JuWGl4Zy1kSlE1cmJaNjlDNzFhTFgtNWN3?oc=5","date":"2024-11-07","type":"pipeline","source":"Pharmaceutical Technology","summary":"DBV Technologies’ stock slides as financial woes worsens - Pharmaceutical Technology","headline":"DBV Technologies’ stock slides as financial woes worsens","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":2,"phase_1":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":5636000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":5636000,"period":"2025-12-31"},{"value":4151000,"period":"2024-12-31"},{"value":4151000,"period":"2024-12-31"},{"value":15728000,"period":"2023-12-31"},{"value":15728000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":116682000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-146947000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":233718000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}